Risk of venous thrombosis with hormone-replacement therapy

Three recent studies show a twofold to fourfold risk of venous thromboembolism with estrogen-only as well as with combined estrogen-progestagen hormone replacement therapy. This risk raises questions about the risks associated with oral contraceptives.

Saved in:
Bibliographic Details
Published inThe Lancet (British edition) Vol. 348; no. 9033; p. 972
Main Authors Vandenbroucke, Jan P, Helmerhorst, Frans M
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 12.10.1996
Elsevier Limited
Subjects
Birth control
Contraceptives
Contraceptives, Oral - adverse effects
Drug therapy
Estrogen Replacement Therapy - adverse effects
Estrogens
Estrogens - adverse effects
Estrogens - chemistry
Female
Health risk assessment
Hemostasis - drug effects
Hormone replacement therapy
Humans
Medical disorders
Progestins - adverse effects
Risk Factors
Thromboembolism
Thrombophlebitis - chemically induced
Online AccessGet full text

Cover

More Information
Summary:Three recent studies show a twofold to fourfold risk of venous thromboembolism with estrogen-only as well as with combined estrogen-progestagen hormone replacement therapy. This risk raises questions about the risks associated with oral contraceptives.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(05)64918-5